LH-IMIDOCARB Injection 12%

Indications

• Bladder irrigation during urological surgery
• Irrigation for transurethral resection of the prostate gland
• Irrigation for bladder tumors

Dosage

Children: Refer to the BNF for Children for pediatric dosing guidelines.

Adults: Refer to the product literature for specific dosing information.

Mechanism of action

Glycine binds to strychnine-sensitive and strychnine-insensitive glycine receptors in the central nervous system. The strychnine-sensitive receptor is a chloride channel that enhances inhibitory neurotransmission. This action may contribute to glycine's potential antispastic effects. Additionally, glycine potentiates NMDA receptor-mediated neurotransmission, which may have implications in managing certain neurological conditions, such as neuroleptic-resistant negative symptoms in schizophrenia.

Pharmacodynamics

Glycine plays a crucial role in various biological functions, including energy metabolism and immune response. It is involved in hormone synthesis and helps in modulating neurotransmitter release, particularly in inhibitory pathways. Glycine's ability to enhance chloride conductance in neurons contributes to its antispastic properties and its potential to mitigate oxidative stress in immune responses.

Pharmacokinetics

Glycine is absorbed readily in the gastrointestinal tract and is utilized by the body for protein synthesis and other metabolic functions. The distribution of glycine in the body is widespread, as it is present in various tissues. Glycine is metabolized in the liver and other tissues, with excretion primarily occurring via the kidneys. The pharmacokinetics of glycine can be influenced by factors such as age, renal function, and overall health status.

Adverse effects

• Fluid overload
• Electrolyte imbalance
• Nausea
• Vomiting
• Headache
• Hypotension

Precautions

• Monitor for signs of fluid overload during irrigation
• Use caution in patients with pre-existing electrolyte imbalances
• Careful consideration in patients with renal impairment

Pregnancy

Glycine is generally considered safe for use during pregnancy when used as an irrigation solution, but risks should be discussed with a healthcare provider.

Breast-feeding

Glycine is likely safe during breastfeeding, but limited data is available. Consultation with a healthcare professional is advisable.

Storage

Store in a cool, dry place. Protect from light. Do not freeze.

Formulations

• Glycine 1.5% irrigation solution 3 litre Easyflow bags
• Glycine 1.5% irrigation solution 1 litre Flowfusor bottles
• Glycine 1.5% irrigation solution 1 litre Easyflow bags
• Glycine 1.5% irrigation solution 2 litre Flowfusor bottles

Dosage

Children: Refer to the specific guidelines and clinical studies for dosing information.

Adults: Refer to the specific guidelines and clinical studies for dosing information.

Mechanism of action

The mechanism of action involves modulation of key biochemical pathways, leading to altered cellular function and therapeutic effects. Specific targets may include receptor interactions, enzyme modulation, and influence on signaling cascades, which contribute to its pharmacological effects.

Pharmacodynamics

Pharmacodynamics refers to the drug's effects on the body, including the relationship between drug concentration and effect. About is believed to exert its effects through interaction with specific receptors, leading to changes in physiological responses. The drug may impact various systems, depending on the targeted pathway, leading to improved clinical outcomes.

Pharmacokinetics

Pharmacokinetics encompasses the absorption, distribution, metabolism, and excretion of About. The drug is expected to be absorbed following administration, with a distribution phase influenced by its solubility and protein-binding characteristics. Metabolism may occur primarily in the liver, and elimination could involve renal or biliary pathways, although specific data on half-life and clearance rates are still under investigation.

Pregnancy

Consult a healthcare provider. Assess risk versus benefit.

Breast-feeding

Consult a healthcare provider. Consider potential effects on the infant.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Electrolyte replacement
• Volume expansion in hypovolemic patients
• Management of hyponatremia
• Support in intravenous fluid therapy

Dosage

Children: Refer to the BNF for Children for appropriate dosing in paediatric patients, as dosages may vary based on the formulation and clinical condition.

Adults: Refer to specific product information or clinical guidelines for dosage recommendations, as disodium is often part of combination products.

Mechanism of action

Disodium compounds often function by providing sodium ions that are essential for various physiological processes. Sodium ions play a critical role in maintaining osmotic balance, nerve impulse transmission, and muscle contraction. In the context of intravenous solutions, disodium helps to restore electrolyte balance in patients.

Pharmacodynamics

The pharmacodynamics of disodium is primarily related to its role in electrolyte balance and fluid homeostasis. Sodium ions are vital for the function of excitable tissues, including neurons and muscle cells. Changes in sodium levels can affect blood pressure, hydration status, and overall cellular function.

Pharmacokinetics

The pharmacokinetics of disodium compounds depend on their specific formulation and route of administration. When administered intravenously, disodium is rapidly distributed in the extracellular fluid, where it helps to maintain osmotic pressure. Sodium is primarily excreted by the kidneys, and its levels can be influenced by fluid intake, dietary sodium, and renal function.

Pregnancy

Use with caution. Consult a healthcare provider for specific guidance.

Breast-feeding

Use with caution. Consult a healthcare provider for specific guidance.

Storage

Store at room temperature, away from moisture and direct sunlight.

Indications

• Lead poisoning
• Mercury poisoning
• Calcium overload
• Certain diagnostic procedures involving heavy metals

Dosage

Children: Refer to the BNF for Children for appropriate dosing information tailored for paediatric patients.

Adults: Refer to the BNF for specific dosing guidelines based on the condition being treated, considering factors such as the severity of metal poisoning and renal function.

Mechanism of action

Edetate functions by forming stable complexes with divalent and trivalent metal ions, including lead and calcium, through its multiple carboxylate and amine groups. This chelation renders the metals more soluble and promotes their renal excretion, thereby reducing their toxic effects in the body.

Pharmacodynamics

The chelation of metals by edetate decreases the free metal concentration in the bloodstream, which mitigates the toxic effects associated with heavy metal accumulation. The efficacy of edetate in removing metals such as lead has been well documented, and its ability to bind calcium can influence calcium homeostasis in certain clinical scenarios.

Pharmacokinetics

Edetate is administered intravenously, with rapid distribution throughout the extracellular fluid. It is primarily excreted unchanged by the kidneys. The onset of action occurs quickly after administration, and the duration depends on the dose and the patient's renal function. The elimination half-life is approximately 1 hour but may vary based on renal clearance.

Contra-indications

• Hypersensitivity to edetate or any component of the formulation
• Severe renal impairment
• Active bleeding disorders

Adverse effects

• Hypocalcemia
• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Headache
• Rash
• Fever

Interactions

• May enhance the effects of anticoagulants
• Concurrent use with calcium supplements may reduce effectiveness
• May interfere with the absorption of certain medications due to changes in gastrointestinal motility

Precautions

• Use with caution in patients with renal impairment
• Monitor electrolyte levels, particularly calcium, during treatment
• Assess the patient's hydration status before administration

Pregnancy

Limited data on the use of edetate in pregnancy. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised as it is not known whether edetate is excreted in human milk. Weigh the risks and benefits before use.

Storage

Store in a cool, dry place, protected from light. Do not freeze.

Formulations

• Edetate disodium injection
• Edetate calcium disodium injection

Indications

• Babesiosis in animals
• Protozoal infections in veterinary medicine

Dosage

Children: For paediatric dosing, consult the BNF for Children for appropriate recommendations.

Adults: For adults, refer to the specific dosage guidelines as per the BNF.

Mechanism of action

Imidocarb exerts its effects by inhibiting the enzyme dihydrofolate reductase, which is crucial for the synthesis of tetrahydrofolate, a form of folic acid necessary for DNA synthesis and cell division in protozoa. This disruption in folate metabolism leads to impaired nucleic acid synthesis, ultimately resulting in cell death.

Pharmacodynamics

The pharmacodynamics of imidocarb involves its action on protozoal organisms, leading to the inhibition of their growth and replication. The drug is effective against both the asexual and sexual stages of Babesia parasites, providing a therapeutic effect in treating infections. Its selectivity for protozoa over mammalian cells contributes to its therapeutic window.

Pharmacokinetics

Imidocarb is well absorbed after parenteral administration, with peak plasma concentrations occurring within a few hours. It is metabolized in the liver and has a half-life that varies depending on the route of administration and the species treated. The drug is excreted primarily via the urine, with some metabolites also eliminated in the feces. Its pharmacokinetic profile may differ amongst species, necessitating careful consideration when dosing.

Contra-indications

• Hypersensitivity to imidocarb or any of its components.
• History of seizures or epilepsy.
• Pregnancy.

Adverse effects

• Drowsiness.
• Ataxia.
• Vagal stimulation leading to bradycardia.
• Tremors.
• Gastrointestinal upset including vomiting and diarrhea.
• Hypersensitivity reactions including rash.

Interactions

• May enhance the effects of other anticholinergic drugs.
• Concurrent use with cholinesterase inhibitors may antagonize the effects of imidocarb.

Precautions

• Use with caution in patients with liver or kidney impairment.
• Monitor for signs of toxicity, especially in patients with a history of seizures.

Pregnancy

Imidocarb should not be used during pregnancy due to potential risk to the fetus.

Breast-feeding

It is not known if imidocarb is excreted in human milk, caution is advised.

Storage

Store in a cool, dry place, protected from light.

Formulations

• Injectable solution.

Indications

• Food preservation
• Antioxidant in pharmaceuticals
• Treatment of certain conditions related to sulfite sensitivity

Dosage

Children: Refer to BNF for Children for appropriate paediatric dosing guidelines.

Adults: Refer to specific formulations and clinical guidelines for appropriate dosing, as it varies based on the condition being treated.

Mechanism of action

Metabisulfite acts primarily as a reducing agent, which means it can donate electrons to other compounds, thereby preventing their oxidation. This property is utilized in food preservation and in various chemical reactions. The compound participates in metabolic pathways such as the thiosulfate oxidation and sulfur oxidation pathways, suggesting its role in sulfur metabolism within certain organisms.

Pharmacodynamics

Metabisulfite's pharmacodynamics involve its role as an antioxidant and a preservative. By preventing the oxidation of sensitive compounds, it helps maintain the stability and efficacy of pharmaceuticals and food products. However, it can also induce allergic reactions in sensitive individuals, particularly in those with asthma.

Pharmacokinetics

Metabisulfite is rapidly absorbed when ingested and is metabolized in the body to sulfate, which is then excreted via the kidneys. Its half-life and specific pharmacokinetic parameters can vary based on the route of administration and individual patient factors.

Indications

• Pain relief
• Anti-inflammatory treatment
• Management of osteoarthritis
• Management of rheumatoid arthritis
• Treatment of dysmenorrhea
• Postoperative pain management

Dosage

Children: Refer to specific propionic acid derivative product monographs for paediatric dosing as it varies by formulation and condition treated.

Adults: Refer to specific propionic acid derivative product monographs for adult dosing as it varies by formulation and condition treated.

Mechanism of action

Propionic acid and its derivatives exert their effects primarily through the inhibition of cyclooxygenase (COX) enzymes, leading to decreased synthesis of prostaglandins. This results in reduced inflammation, pain, and fever. By blocking COX-1 and COX-2 pathways, propionic compounds modulate the inflammatory response and provide analgesic effects.

Pharmacodynamics

Propionic compounds have a rapid onset of action, with effects noticeable within 30 minutes to an hour after administration. The anti-inflammatory effects are dose-dependent, and the duration of action typically lasts for several hours. The analgesic properties are also evident in acute and chronic pain management, providing relief from conditions such as arthritis, menstrual pain, and musculoskeletal disorders.

Pharmacokinetics

After oral administration, propionic acid is rapidly absorbed from the gastrointestinal tract. It is primarily metabolized in the liver, undergoing glucuronidation and oxidation. The elimination half-life of propionic derivatives varies but generally ranges from 1 to 4 hours. These substances are excreted primarily through urine, with a small fraction eliminated in feces. Due to their short half-lives, multiple dosing may be required to maintain therapeutic levels.

Contra-indications

• Hypersensitivity to propionic acid or its derivatives
• Active peptic ulcer disease
• Severe renal impairment

Adverse effects

• Gastrointestinal disturbances (nausea, vomiting, diarrhea)
• Dizziness
• Headache
• Rash
• Tinnitus
• Hepatotoxicity (rare)

Interactions

• Increased risk of gastrointestinal bleeding with NSAIDs
• Inhibition of renal excretion of certain drugs (e.g., lithium)
• Potential additive effects with other central nervous system depressants

Precautions

• Use with caution in patients with renal or hepatic impairment
• Monitor for signs of gastrointestinal bleeding in long-term use
• Caution in patients with asthma, as propionic acid derivatives may exacerbate symptoms

Pregnancy

Use in pregnancy only if clearly needed. Animal studies have shown adverse effects. There is limited data on human pregnancy.

Breast-feeding

Use with caution while breastfeeding. Propionic acid and its derivatives may pass into breast milk.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Formulations

• Oral tablets
• Oral suspension
• Topical formulations (creams, gels)

Mechanism of action

In the CNS, there exist strychnine-sensitive glycine binding sites as well as strychnine-insensitive glycine binding sites. The strychnine-insensitive glycine-binding site is located on the NMDA receptor complex. The strychnine-sensitive glycine receptor complex is comprised of a chloride channel and is a member of the ligand-gated ion channel superfamily. The putative antispastic activity of supplemental glycine could be mediated by glycine's binding to strychnine-sensitive binding sites in the spinal cord. This would result in increased chloride conductance and consequent enhancement of inhibitory neurotransmission. The ability of glycine to potentiate NMDA receptor-mediated neurotransmission raised the possibility of its use in the management of neuroleptic-resistant negative symptoms in schizophrenia. Animal studies indicate that supplemental glycine protects against endotoxin-induced lethality, hypoxia-reperfusion injury after liver transplantation, and D-galactosamine-mediated liver injury. Neutrophils are thought to participate in these pathologic processes via invasion of tissue and releasing such reactive oxygen species as superoxide. In vitro studies have shown that neutrophils contain a glycine-gated chloride channel that can attenuate increases in intracellular calcium and diminsh neutrophil oxidant production. This research is ealy-stage, but suggests that supplementary glycine may turn out to be useful in processes where neutrophil infiltration contributes to toxicity, such as ARDS. HYPERPOLARIZATION OF MOTONEURONS PRODUCED BY IONTOPHORETIC APPLICATION OF GLYCINE IS RELATIVELY TRANSIENT BUT APPROACHES THE EQUILIBRIUM POTENTIAL FOR THE INDIRECTLY ACTIVATED INHIBITORY POSTSYNAPTIC POTENTIAL...TESTS WITH GABA... INDICATE SIMILAR ELECTROPHYSIOLOGICAL EFFECTS & SIMILAR INCR IN CL- CONDUCTANCE. MAJOR EVIDENCE THAT FAVORS GLYCINE AS MEDIATOR OF INTRASPINAL POSTSYNAPTIC INHIBITION IS THE SELECTIVE ANTAGONISM OF ITS EFFECTS BY STRYCHNINE. ... GLYCINE ALSO APPEARS TO BE MOST LIKELY TRANSMITTER FOR INHIBITORY INTERNEURONS IN RETICULAR FORMATION BUT NOT IN CUNEATE NUCLEUS.

Pharmacodynamics

Helps trigger the release of oxygen to the energy requiring cell-making process; Important in the manufacturing of hormones responsible for a strong immune system.